Oct 02nd 2013 - Edison Investment Research today published a report on CytRx Corporation entitled "ECC Update: Aldoxorubicin Trumps Doxorubicin". In summary, the report says:
New aldoxorubicin data suggest efficacy and safety advantages over doxorubicin in soft tissue sarcoma (STS) and glioblastoma (GBM). Based on detailed preclinical GBM data, the FDA (and physicians) have endorsed plans to start Phase II development in Q413. Separately, initial Phase IIb data in front-line STS raise hopes that aldoxorubicin will meet its primary PFS end point. Our rNPV is maintained at $152m or $5.00/share.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »